CORRECTION article

Front. Immunol., 16 January 2024

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1365027

Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

  • 1. Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

  • 2. Institute of Immunology, University of Science and Technology of China, Hefei, China

  • 3. Hefei TG ImmunoPharma Corporation Limited, Hefei, China

In the published article, there was an error in the funding statement for the National Key R&D Program of China (2019YFA0508502/3, 2018YFA0507403); Natural Science Foundation of China (8222053, 81972679); Natural Science Foundation of Anhui Province (2008085MH252). The correct Funding statement appears below.

Statements

Funding

This work was supported by the National Key R&D Program of China (2019YFA0508502/3, 2018YFA0507403); Natural Science Foundation of China (82222053, 81972679); Natural Science Foundation of Anhui Province (2008085MH252).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

NK-cell engager, T-cell engager, tumor immunotherapy, antitumor, proinflammatory cytokines

Citation

Xiao X, Cheng Y, Zheng X, Fang Y, Zhang Y, Sun R, Tian Z and Sun H (2024) Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Front. Immunol. 15:1365027. doi: 10.3389/fimmu.2024.1365027

Received

03 January 2024

Accepted

05 January 2024

Published

16 January 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2024

Updates

Copyright

*Correspondence: Haoyu Sun, ; Zhigang Tian,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics